PARP7 inhibitor BY101921

An orally available inhibitor of the nuclear enzyme poly (ADP-ribose) polymerase (PARP) 7, with potential immunomodulating and antineoplastic activities. Upon oral administration, PARP7 inhibitor BY101921 targets, binds to, and inhibits the activity of PARP7, which restores type I interferon (IFN) signaling. This may lead to the induction of both innate and adaptive immune responses, and the inhibition of tumor growth and proliferation. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins that signal and recruit other proteins to repair damaged DNA.